Fate Therapeutics Inc DEFA14A, filed Apr 21, 2023
Fate Therapeutics Inc (FATE)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement | |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ☐ | Definitive Proxy Statement | |
| ☒ | Definitive Additional Materials | |
| ☐ | Soliciting Material under §240.14a-12 | |
Fate Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ |
No fee required. | |
| ☐ |
Fee paid previously with preliminary materials. | |
| ☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | |
P.O. BOX 8016, CARY, NC 27512-9903
Fate Therapeutics, Inc.
Important Notice Regarding the Availability of Proxy Materials
for the Shareholder Meeting to be held on June 6, 2023
For Stockholders of record as of April 11, 2023
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.
To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/FATE
To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.
Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.
|
For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/FATE
Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.
|
| ||||||
|
If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 26, 2023. |
To order paper materials, use one of the following methods.
|
INTERNET |
TELEPHONE |
|
||||||||||
| www.investorelections.com/FATE | (866) 648-8133 | paper@investorelections.com | ||||||||||
| When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above. |
* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. |
|||||||||||
|
Fate Therapeutics, Inc.
| ||||||
| Meeting Type: Annual Meeting of Stockholders | ||||||
| Date: | Tuesday, June 6, 2023 | |||||
| Time: | 9:00 AM, Pacific Time | |||||
| Place: | Fate Therapeutics, Inc. | |||||
| 12278 Scripps Summit Drive, San Diego, California 92131 | ||||||
|
SEE REVERSE FOR FULL AGENDA
| ||||||
Fate Therapeutics, Inc.
Annual Meeting of Stockholders
THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR PROPOSALS 1, 2 AND 3
PROPOSAL
| 1. | Election of Class I Directors |
Nominees
1.01 Robert S. Epstein, M.D., M.S.
1.02 John D. Mendlein, Ph.D., J.D.
1.03 Karin Jooss, Ph.D.
| 2. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. |
| 3. | To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. |
| Note: | To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. |